Contineum Therapeutics (NASDAQ:CTNM) Sets New 12-Month High at $20.97

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) hit a new 52-week high during trading on Wednesday . The company traded as high as $20.97 and last traded at $20.67, with a volume of 56097 shares traded. The stock had previously closed at $19.93.

Wall Street Analysts Forecast Growth

CTNM has been the subject of several analyst reports. Stifel Nicolaus initiated coverage on Contineum Therapeutics in a research report on Tuesday, April 30th. They set a “buy” rating and a $29.00 target price for the company. Morgan Stanley started coverage on Contineum Therapeutics in a report on Tuesday, April 30th. They set an “overweight” rating and a $25.00 price objective on the stock. Finally, Royal Bank of Canada started coverage on Contineum Therapeutics in a research note on Tuesday, April 30th. They issued an “outperform” rating and a $30.00 target price on the stock.

Contineum Therapeutics Stock Up 4.4 %

The company has a 50-day moving average of $16.11.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($3.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($3.02). As a group, equities research analysts predict that Contineum Therapeutics, Inc. will post -1.95 earnings per share for the current year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).